Cell-based Therapy for the Treatment of Kidney Disease
Early Phase 1
Not yet recruiting
- Conditions
- Kidney Diseases
- Interventions
- Biological: endothelial progenitor cell
- Registration Number
- NCT04187625
- Lead Sponsor
- Brigham and Women's Hospital
- Brief Summary
Endothelial progenitor cells derived from and delivered to the renal vasculature may be stimulated to initiate differentiation programs during episodes of injury. It is hypothesized that endothelial progenitor cells from the kidney can transition to a phenotype that promotes endothelial repair.
- Detailed Description
This is an interventional study involving patients that have a diagnosis of chronic kidney disease. Patients will have at least stage 3 chronic kidney disease stage or greater. Kidney-derived endothelial progenitor cells will have been obtained using associated protocols that are currently approved by the Partners Human Research Committee.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
- Enrolled patients will have endothelial progenitor cells previously acquired.
Exclusion Criteria
- Patients without previously acquired endothelial progenitor cells will be excluded.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Intervention endothelial progenitor cell Patients will be given autologous endothelial progenitor cells
- Primary Outcome Measures
Name Time Method Safety of progenitor cell delivery 180 days Serum creatinine will be measured after cell delivery
- Secondary Outcome Measures
Name Time Method